Reduced Sodium GHB Salt Formulations for Sleep Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current GHB formulations, such as Xyrem®, pose a high sodium intake issue for patients with hypertension, heart disease, or at risk of stroke, and there is a need for alternatives that minimize sodium while maintaining therapeutic efficacy and bioequivalence.
Innovation Solution
Development of pharmaceutical compositions comprising salts of gamma-hydroxybutyrate (GHB) with reduced sodium content, using cations like potassium, calcium, and magnesium, which are bioequivalent to Xyrem®, to treat fibromyalgia and sleep disorders, and are formulated to provide stable, effective, and consistent doses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If sodium oxybate (Xyrem®) is used to treat narcolepsy and fibromyalgia, then therapeutic efficacy is achieved, but sodium intake significantly increases which is harmful to patients with hypertension, heart disease, renal disease or at risk of stroke
Solution Approach 1:
The patent changes the chemical composition parameter by replacing sodium cations with alternative cations (potassium, calcium, magnesium) in the GHB salt formulations. This parameter change maintains the therapeutic anion (GHB) while modifying the cation to reduce harmful sodium intake, directly resolving the contradiction between efficacy and sodium-related harm
Solution Approach 2:
The patent creates composite salt formulations containing multiple cations (e.g., potassium, calcium, magnesium) combined with GHB anions. These composite materials provide therapeutic GHB effects while distributing the cation load across multiple elements, reducing reliance on sodium and minimizing cardiovascular and renal risks associated with high sodium intake
2Object-affected harmful factors
If GHB formulations use alternative cations to reduce sodium content, then sodium intake is minimized, but solubility and stability may be compromised
Solution Approach 1:
The patent systematically evaluates and adjusts formulation parameters including pH, buffer capacity, and cation ratios to optimize solubility and stability of alternative cation GHB salts. By modifying these parameters, the formulation maintains adequate solubility for bioequivalence while achieving reduced sodium content
Solution Approach 2:
The patent introduces buffering agents and pH-adjusting components as intermediaries to stabilize the alternative cation GHB formulations. These intermediaries help maintain optimal pH ranges that enhance solubility and chemical stability of the non-sodium cation salts, preventing precipitation and degradation while preserving therapeutic efficacy
3Object-affected harmful factors
If GHB formulations use alternative cations to reduce sodium content, then sodium intake is minimized, but bioequivalence to Xyrem® must be maintained
Solution Approach 1:
The patent carefully adjusts formulation parameters including GHB concentration, cation ratios, pH, and buffer capacity to ensure that alternative cation formulations achieve bioequivalence to sodium oxybate. By optimizing these parameters, the patent maintains comparable pharmacokinetic profiles (absorption, distribution, metabolism, excretion) while reducing sodium content
Solution Approach 2:
The patent creates alternative cation GHB formulations that copy the therapeutic mechanism and pharmacokinetic behavior of sodium oxybate. By replicating the key functional aspects (GHB delivery, absorption rate, plasma concentration profile) using different cations, the patent achieves bioequivalence in terms of therapeutic effect while eliminating the harmful sodium component
Data Source
AI summary
Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (GHB). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.